Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 6/20 | 0.50 |
| ▸ | PRKDC | P78527 | 4/20 | 0.50 |
| ▸ | LDHA | P00338 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619632 | 0.86 | IKBKB (0.64) | IKBKBATRPRKDCATMAKR1B1 | |
| SCHEMBL6987949 | 0.86 | IKBKB (0.51) | IKBKBATRPRKDCLDHAATM | |
| SCHEMBL3461817 | 0.82 | IKBKB (0.49) | IKBKBATRPRKDCATMALDH1A1 | |
| SCHEMBL20899047 | 0.81 | LDHA (0.50) | IKBKBATRPRKDCLDHAATM | |
| SCHEMBL318797 | 0.81 | ATR (0.68) | IKBKBATRPRKDCATM | |
| SCHEMBL26986900 | 0.79 | IKBKB (0.48) | IKBKBATRPRKDCLDHAAKR1B1 | |
| SCHEMBL28918651 | 0.77 | ALDH1A1 (0.56) | IKBKBATRPRKDCLDHAALDH1A1 | |
| SCHEMBL319167 | 0.77 | ASIC3 (0.57) | IKBKBATRPRKDCLDHAATM | |
| SCHEMBL11146891 | 0.76 | IKBKB (0.60) | IKBKBATRPRKDCLDHAATM | |
| SCHEMBL28283875 | 0.76 | BCHE (0.46) | ATRALDH1A1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007050383-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050401-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, RET | IKBKB 576/4885ATR 907/4885PRKDC 83/4885 |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | IKBKB 413/4885ATR 4853/4885PRKDC 4822/4885 |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | IKBKB 440/4885ATR 1059/4885PRKDC 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.